UA138842U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of endothelin, transforming growth factor beta 1 (TGF-b1), C-reactive protein (SRP), interleukin 6 (IL-6), homocysteine. With a homozygous carrier of 786-CC, endothelin levels> 10 ng / ml, TGF-b1 <14 ng / ml, PSA> 6 mg / l, IL-6> 10 ng / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

The proposed useful model, a method of predicting the development of osteoarthritis, belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the nitric oxide synthase gene (6eMO5 17860), the content of endothelin, transforming growth factor beta 1 (TGF-B1), C-reactive protein (CRP), is determined in the patient's blood serum. interleukin 6 (IL-b), homocysteine and with homozygous carrier 786-SS, endothelin levels 210 ng/ml, TFR-B1 "14 ng/ml, SRP "6b mg/l, IL-6 "10 ng/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the eMmo5 1786C gene polymorphism is determined, the endothelin content is determined by the immunoenzymatic method,

TFR-VI, SRP, IL-6, homocysteine. With homozygous carrier 786-SS and levels of endothelin 210 ng/ml, TFR-B1 "14 ng/ml, SRP "6 mg/l, IL-6 "10 ng/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method.

Patient S., 65 years old, was hospitalized in the clinic due to pain syndrome in the right hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. The eMO5 1786C gene polymorphism and the content of endothelin, TFR-B1, SRP, IL-6, and homocysteine were determined in the serum. A homozygous carrier of 786-SS was established, endothelin levels - 23 ng/ml, TFR-VI - 7.6 ng/ml, SRP - 15 mg/l, IL-b - 22 ng/l, homocysteine - 45 μmol/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed

From the phenomenon of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (EMO5 T786C), the content of endothelin, transforming growth factor beta 1 (TGF-RI), C-reactive protein (SRP), interleukin 6 (IL-6), homocysteine and with homozygous carrier 786-SS, endothelin levels 210 ng/ml, TFR-DI "14 ng/ml, SRP "6 mg/l, IL-6 "10 ng/l, homocysteine 220 μmol/l predict the development of osteoarthritis.